Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …

Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with
historically high mortality rates. The standard of care treatment remained unchanged for …

Progress in acute myeloid leukaemia treatment is occurring at an unprecedented pace. The
past decade has witnessed an increasingly improved scientific understanding of the …

With rapid advances in sequencing technologies, tremendous progress has been made in
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …

PURPOSE TP53-mutated (TP53m) myelodysplastic syndromes (MDS) and acute myeloid
leukemia (AML) have very poor outcome irrespective of the treatment received, including …

Background Venetoclax combined with hypomethylating agents is a new standard of care
for newly diagnosed patients with acute myeloid leukaemia (AML) who are 75 years or …

Advances in molecular biology, microfluidics and bioinformatics have empowered the study
of thousands or even millions of individual cells from malignant tumours at the single-cell …

TP53-mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) form a
distinct group of myeloid disorders with dismal outcomes. TP53-mutated MDS and AML …

The nucleophosmin (NPM1) gene encodes for a multifunctional protein with prominent
nucleolar localization that shuttles between nucleus and cytoplasm. NPM1 mutations …

Until recently, acute myeloid leukemia (AML) patients used to have limited treatment options,
depending solely on cytarabine+ anthracycline (7+ 3) intensive chemotherapy and …